Cost-effectiveness analysis of biological treatments for rheumatoid arthritis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 3, 2004, Pages 307-315

  Chiou, Chiun Fang ^a   Choi, Julie ^b   Reyes, Carolina M ^b  

^a CERNER CORPORATION   (United States)

^b Cerner Health Insights   (United States)

Author keywords

Cost effectiveness analysis; Preference weight; Quality adjusted life year; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ASTHENIA; BIOLOGICAL THERAPY; BODY WEIGHT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; INJECTION SITE REACTION; MANAGED CARE ORGANIZATION; MEDICAL SOCIETY; MONOTHERAPY; PHARYNGITIS; PNEUMONIA; PREDICTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SEPSIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 2942513199     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.3.307     Document Type: Review

References (27)

1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4(Suppl. 3), S265-S272 (2002).
2. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 42, 415-420 (1999).
3. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39, 713-722 (1996).
4. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 3, 243-252 (2000).
5. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J. Rheumatol. 53 (Suppl.), 8-12 (1998).
6. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443-1450 (2002).
7. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
8. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a 24-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624 (2002).
9. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
10. Klareskog L, van der HD, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
11. Chiou CF, Weisman M, Sherbourne CD et al. Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. Annual European Congress of Rheumatology EULAR, Berlin, Germany, June (2004).
12. Abbott Laboratories. Humira™ (adalimumab) Prescribing Information. Package Insert. (2003).
13. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
14. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998).
15. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Interm. Med. 130, 478-486 (1999).
16. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
17. Average Wholesale Price. First DataBank. (2003).
18. Anonymous. 2003 CPT Expert. Second Edition. Ingenix Publishing Group, UT, USA (2002).
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 30, 473-483 (1992).
20. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J. Rheumatol. 9, 789-793 (1982).
21. Wong AL, Wong WK, Harker J et al. Patient self-report tender and swollen joint counts in early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J. Rheumatol. 26, 2551-2561(1999).
22. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326-335 (2003).
23. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400-408 (2002).
24. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheumatism. 43, 2316-2327 (2000).
25. Amgen. Anakinra (Kineret®) Prescribing Information. (2003).
26. Burmester GR, van de Putte BA, Rau R, Breedveld F. Long-term effectiveness and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheumatoid arthritis. Paper presented at 66th Annual Scientific Meeting of the American College of Rheumatology, LA, USA (2002).
27. Centocor. Infliximab (Remicade®) Prescribing Information. Package Insert. (2003).